13 Apheresis therapy showed its high safety and adequate efficacy for the treatment of patients with ulcerative colitis - the postmarketing surveillance of more than 600 ulcerative colitis patients in Japan

Optimal apheresis treatment volume for t

Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with cellsorba in patients with active ulcerative colitis

✍ Ken Fukunaga; Koji Kamikozuru; Yoko Yokoyama; Nobuyuki Hida; Yoshio Ohda; Naohis 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

## Abstract **Background**: Leukocytapheresis (LCAP) is used as an adjunct therapy for patients with active ulcerative colitis (UC). Although, LCAP is routinely performed at 3,000 mL per session, we were interested to see that if this can be replaced with bodyweight (BW) adjusted volume. **Methods*